



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

January 17th 6:00 – 8:30 p.m.

- | | |
|--|---|
| <ul style="list-style-type: none">▪ Executive Session▪ Introductions and Approval of DUR Board Minutes
(Public Comment Prior to Board Action)▪ DVHA Pharmacy Administration Updates<ul style="list-style-type: none">▪ Discussion of Act 172, Sec. E.306.11: Prescribing Practices;
Drug Utilization Review Board; Report▪ Medical Director Update<ul style="list-style-type: none">▪ Clinical Programs Update▪ Prescriber Comments▪ Follow-up Items from Previous Meetings▪ RetroDUR/DUR<ul style="list-style-type: none">▪ Introduce: Long Term use of Skeletal Muscle Relaxants▪ Data presentation: Compliance with GLP-1 Agonists
in Type II Diabetes▪ Review of Newly-Developed/Revised
(Public comment prior to Board action)▪ Clinical Update: Drug Reviews
(Public comment prior to Board action) | <p>6:00 - 6:30</p> <p>6:30 - 6:35</p> <p>6:35 - 6:40</p> <p>6:40 – 6:45</p> <p>6:45 – 6:45</p> <p>6:45 – 7:00</p> <p>7:00 – 7:00</p> <p>7:00 – 7:45</p> |
|--|---|

Abbreviated New Drug Reviews

- None

Full New Drug Reviews

- Afstyla®(antihemophilic factor, recombinant) (included in the Hemophilia Factor Therapeutic Drug Class Review)
- Bevespi® Aero (glycopyrrolate/formoterol)
- Briviact® (brivaracetam)
- Jentadueto® XR (linagliptin &metformin extended- release)
- Nuplazid® (pimavanserin)
- Probuphine® (buprenorphine) (included in the Opiate Dependence Agents Review)
- Vonvendi® (von Willebrand factor, recombinant) (included in the Hemophilia Factor Therapeutic Drug Class Review)
- Xiidra® (lifitegrast)

- Xtampza® ER (oxycodone extended-release)
- **New Managed Therapeutic Drug Classes** **7:45-7:45**
(Public comment prior to Board action)
- **Therapeutic Drug Classes – Periodic Review** **7:45 – 8:15**
(Public comment prior to Board action)
 - Androgenic Agents
 - Antifungals, Topical
 - Anti-parasitics, Topical
 - Antivirals, Oral
 - Antivirals, Topical
 - Atopic, Dermatitis
 - Hemophilia Factor
 - H. Pylori
 - Opiate Dependence Agents
- **Review of Newly-Developed/Revised**
(Public comment prior to Board action)
- **General Announcements** **8:15 – 8:30**
Selected FDA Safety Alerts
 - **Products Containing Belladonna Extract by Raritan Pharmaceuticals: Recall - Possible Belladonna Alkaloids**
<http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm530642.htm>
 - **General Anesthetic and Sedation Drugs: Drug Safety Communication - New Warnings for Young Children and Pregnant Women**
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm533195.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
 - **FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes**
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery
- **Adjourn** **8:30**